Denosumab, a monoclonal antibody against the receptor activator for nuclear factor-kappa B ligand (RANKL), is a recently approved antiresorptive drug that suppresses osteoclast formation by targeting preosteclasts, in contrast to the traditional antiresorptive bisphosphonates that target mature osteoclasts. Osteonecrosis of the jaw (ONJ) is a well-known, if rare, side effect of bisphosphonate therapy; however, cases of ONJ have also been reported since 2010 in patients taking denosumab. We describe here a patient who developed ONJ while receiving denosumab; the pharmacokinetics of denosumab and bisphosphonates are discussed in the context of ONJ management.
|Number of pages||6|
|Journal||Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology|
|Publication status||Published - 2015 Nov|
Bibliographical noteFunding Information:
This research was supported by a Basic Science Research Program through the National Research Foundation of Korea, funded by the Ministry of Science, ICT, and Future Planning (NRF-2013 R1 A1 A 1009513).
© 2015 Elsevier Inc.
All Science Journal Classification (ASJC) codes
- Oral Surgery
- Pathology and Forensic Medicine
- Dentistry (miscellaneous)
- Radiology Nuclear Medicine and imaging